Sernova Biotherapeutics

Vertex remains bullish on prospects for developing curative, endogenous insulin-sparing cell therapies for type 1 diabetes, despite disappointing results unveiled on 28 March that led the Boston-based

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b

Several companies are developing islet cell-based therapies for type 1 diabetes, and all face the same two problems: avoiding the host’s immune response to foreign tissue, and manufacturing at scale.

Sernova Corp is working to develop a functional cure for type 1 diabetes that could free patients from a lifetime of insulin injections, but despite some early encouraging clinical data and a potenti